|
Medicare’s Coverage Of Colorectal Cancer Drugs: A Case Study In Evidence Development And Policy
Tanisha Carino,
Reginald D. Williams, II,
Allison M. Colbert and
Perry Bridger
Payers point to the lack of unbiased evidence for making coverage decisions for new and often costly technologies. This paper provides a case study of a new approach to developing information to meet the needs of a payer: Medicare’s coverage with evidence development (CED) policy. Medicare’s decision to condition coverage of cancer therapies on clinical trial participation is an early application of CED and signals Medicare’s interest in developing evidence on new technologies for beneficiaries. This paper reviews the rationale and challenges Medicare faces in applying its CED policy and discusses the implications of payers’ using and generating evidence.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
P. J. Neumann, M. S. Kamae, and J. A. Palmer
Medicare's National Coverage Decisions For Technologies, 1999-2007
Health Aff.,
November 1, 2008;
27(6):
1620 - 1631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Redberg
Evidence, Appropriateness, And Technology Assessment In Cardiology: A Case Study Of Computed Tomography
Health Aff.,
January 1, 2007;
26(1):
86 - 95.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Tunis and S. D. Pearson
Coverage Options For Promising Technologies: Medicare's 'Coverage With Evidence Development'
Health Aff.,
September 1, 2006;
25(5):
1218 - 1230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Keenan, P. J. Neumann, and K. A. Phillips
Biotechnology And Medicare's New Technology Policy: Lessons From Three Case Studies
Health Aff.,
September 1, 2006;
25(5):
1260 - 1269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
